HC Wainwright Has Bearish Estimate for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Xenon Pharmaceuticals in a report released on Monday, February 24th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($1.00) per share for the quarter, down from their previous estimate of ($0.88). HC Wainwright has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($1.09) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($4.64) EPS, FY2026 earnings at ($5.74) EPS, FY2027 earnings at ($6.12) EPS, FY2028 earnings at ($5.58) EPS and FY2029 earnings at ($4.03) EPS.

A number of other research analysts also recently commented on XENE. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Stock Down 1.9 %

Shares of NASDAQ:XENE opened at $37.65 on Wednesday. Xenon Pharmaceuticals has a 12-month low of $35.53 and a 12-month high of $50.99. The company has a market cap of $2.87 billion, a P/E ratio of -13.35 and a beta of 1.20. The company’s fifty day moving average is $39.32 and its two-hundred day moving average is $40.34.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in XENE. FMR LLC raised its holdings in Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock worth $294,991,000 after acquiring an additional 607,606 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after purchasing an additional 15,226 shares in the last quarter. Braidwell LP boosted its holdings in shares of Xenon Pharmaceuticals by 7.6% in the 4th quarter. Braidwell LP now owns 2,913,964 shares of the biopharmaceutical company’s stock valued at $114,227,000 after buying an additional 206,709 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Xenon Pharmaceuticals by 12.3% in the fourth quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company’s stock valued at $112,425,000 after buying an additional 314,363 shares in the last quarter. Finally, Polar Capital Holdings Plc increased its holdings in Xenon Pharmaceuticals by 10.3% during the fourth quarter. Polar Capital Holdings Plc now owns 2,697,657 shares of the biopharmaceutical company’s stock worth $105,748,000 after buying an additional 253,012 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,492 shares of company stock worth $2,334,969. Insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.